Comparative Pharmacology
Head-to-head clinical analysis: GRISEOFULVIN versus HEAD SHOULDERS CONDITIONER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRISEOFULVIN versus HEAD SHOULDERS CONDITIONER.
GRISEOFULVIN vs HEAD & SHOULDERS CONDITIONER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to microtubular protein tubulin, disrupting mitotic spindle formation and inhibiting fungal cell mitosis. Also interferes with fungal nucleic acid synthesis and cell wall deposition.
Not applicable; this is a cosmetic conditioner. No pharmacological mechanism.
500 mg orally once daily or 250 mg orally twice daily; microsize formulation: 500-1000 mg orally once daily; ultramicrosize formulation: 330-375 mg orally once daily. Administer with fatty meal to enhance absorption.
Not applicable. Head & Shoulders Conditioner is a cosmetic product for external use on hair and scalp; no systemic dosing.
None Documented
None Documented
Terminal elimination half-life is 9 to 24 hours; clinically, it allows once or twice daily dosing.
Clinical Note
moderateGriseofulvin + Estrone sulfate
"The metabolism of Estrone sulfate can be increased when combined with Griseofulvin."
Clinical Note
moderateGriseofulvin + Tranilast
"The risk or severity of adverse effects can be increased when Griseofulvin is combined with Tranilast."
Clinical Note
moderateGriseofulvin + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Griseofulvin is combined with Tolfenamic acid."
Clinical Note
moderateGriseofulvin + Nimesulide
Not applicable for systemic elimination; local retention on hair/scalp lasts until next wash (typically 24-48 hours).
Primarily hepatic metabolism; less than 1% excreted unchanged in urine; metabolites excreted in urine (approximately 50%) and feces (approximately 36%) within 24 hours.
Renal (urine): <1% unchanged; biliary/fecal: <1% as parent compound; majority remains on hair/scalp and is removed via washing and shedding. Systemic absorption negligible.
Category D/X
Category C
Antifungal
Antifungal/Antidandruff
"The risk or severity of adverse effects can be increased when Griseofulvin is combined with Nimesulide."